Basilea Pharmaceutica Ltd. Logo
 
Search
 

News

 
 
Language
Year
Keyword
 
Thursday, August 10. 2017
 
  • Completed license agreement with Pfizer for Cresemba in Europe (excluding Nordics), Russia, Turkey and Israel; CHF 70 million upfront payment and up to USD 427 million in milestones
  • 56 percent increase in total revenue, amounting to CHF 46.2 million
  • BARDA committed USD 54.8 million in additional funding to support phase 3 development of ceftobiprole for registration in the U.S.
  • Agreement with Adult Brain Tumor Consortium for phase 1 clinical study to explore BAL101553 in newly diagnosed glioblastoma
 
more...
 
Thursday, July 20. 2017
 
Basel, Switzerland, July 20, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its license agreement with Pfizer Inc. (NYSE: PFE) for Basilea's antifungal Cresemba (isavuconazole), which was announced on June 14, has completed and therefore will now be implemented.
 
more...
 
Wednesday, June 14. 2017
 
  • Basilea receives a CHF 70 million upfront payment and is eligible for additional milestone payments of up to USD 427 million and double-digit royalties on sales
  • Basilea continues to focus on establishing further partnerships for the commercialization of its anti-infectives Cresemba and Zevtera in key markets around the world
  • Basilea explores partnering opportunities to further strengthen its anti-infectives and oncology R&D portfolio

 
more...
 
Wednesday, June 14. 2017
 
Basel, Switzerland, June 14, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a distribution and license agreement with Avir Pharma Inc. (Avir) for Basilea's antifungal Cresemba® (isavuconazole) and antibiotic Zevtera® (ceftobiprole) in Canada.
 
more...
 
Tuesday, June 13. 2017
 
Basel, Switzerland, June 13, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has been awarded USD 54.8 million for two additional options on its existing contract with the Biomedical Advanced Research and Development Authority (BARDA), the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response under Contract No. HHSO100201600002C, to support the phase 3 development of ceftobiprole. The total potential funding of up to approximately USD 108 million under the contract will enable Basilea to conduct two clinical phase 3 studies to evaluate Basilea's antibiotic ceftobiprole for the treatment of Staphylococcus aureus bacteremia (bloodstream infections) and acute bacterial skin and skin structure infections. The cross-supportive studies are part of the clinical phase 3 program aiming at regulatory approval of ceftobiprole in the United States.
 
more...
 
Monday, June 12. 2017
 
  • The Adult Brain Tumor Consortium (ABTC) is designed to develop more effective treatments for malignant brain tumors. It is funded by the US National Cancer Institute (NCI).
  • The ABTC will conduct a clinical phase 1 study to determine the safety and tolerability of Basilea's novel tumor checkpoint controller BAL101553 in newly diagnosed glioblastoma patients.
 
more...
 
Tuesday, June 06. 2017
 
Basel, Switzerland, June 6, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that updates were presented on the ongoing clinical phase 1/2a program with its anticancer drug candidate BAL101553, a novel tumor checkpoint controller, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 2-6, 2017.
 
more...
 
Friday, June 02. 2017
 
Basel, Switzerland, June 2, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced that, as of August 1, 2017, Damian Heller will assume the role of General Counsel & Corporate Secretary and join the Extended Management Committee which reports to the CEO. Mr. Heller succeeds Elizabeth Rozek who will be leaving Basilea to relocate to the United States.
 
more...
 
Thursday, April 27. 2017
 
Basel, Switzerland, April 27, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that at today's Ordinary General Meeting of Shareholders for the financial year 2016, shareholders approved all agenda items proposed by the Board of Directors.
 
more...
 
Friday, April 21. 2017
 
  • Initiation of ceftobiprole pivotal phase 3 clinical program under BARDA contract anticipated within the next three to six months
 
more...
 
more
Info